Author:
Vissichelli Nicole C.,Stevens Michael P.
Publisher
Springer Science and Business Media LLC
Reference131 articles.
1. Talbot GH, Jezek A, Murray BE, Jones RN, Ebright RH, Nau GJ, et al. The Infectious Diseases Society of America’s 10 × ‘20 initiative (ten new systemic antibacterial agents FDA-approved by 2020): Is 20 × ’20 a possibility? Clin Infect Dis. 2019. [Epub ahead of print].
2. Antimicrobial resistance global report on surveillance. World Health Organization. 2014. [Internet] [cited 2019 02 18]. Available from:
https://apps.who.int/iris/bitstream/handle/10665/112642/9789241564748_eng.pdf;jsessionid=33FAEEDFE1183392D13CD4E1139521BC?sequence=1
3. U.S. challenges world to intensify global fight against antibiotic resistance | CDC Online Newsroom | CDC [Internet]. [cited 2019 Feb 18]. Available from:
https://www.cdc.gov/media/releases/2018/p0925-global-antibiotic-resistance.html
4. Saisho Y, Katsube T, White S, Fukase H, Shimada J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects. Antimicrob Agents Chemother. American Society for Microbiology Journals. 2018;62:e02163–17.
5. Katsube T, Miyazaki S, Narukawa Y, Hernandez-Illas M, Wajima T. Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters. Eur J Clin Pharmacol. Springer, Berlin. 2018;74:931–8.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Newer Antibiotic Agents in Pipeline;Beta-Lactam Resistance in Gram-Negative Bacteria;2022